Windtree Therapeutics, a Nasdaq-listed biotech firm, has announced plans to purchase up to $700 million in BNB, the fifth-largest cryptocurrency, to bolster its balance sheet. Following BNB's recent all-time high of $808, Windtree is raising funds for these purchases through a $500 million equity line of credit from an unidentified institutional investor and a $20 million stock purchase agreement with Build and Build Corp. The company previously set out a plan to buy $200 million worth of BNB and will collaborate with Kraken for asset custody. Although Windtree's stock fell about 5% following the announcement, it has risen by 162% over the past month. This move reflects a growing trend among publicly traded companies, including Windtree and Chinese firm Nano Labs, to integrate cryptocurrencies into their treasury strategies as they seek to enhance stock value.

Source 🔗